WO1992018630A1 - Compose comprenant une sequence peptidique neutralisant l'infection par le cytomegalovirus humain (hcmv) et composition le comportant - Google Patents

Compose comprenant une sequence peptidique neutralisant l'infection par le cytomegalovirus humain (hcmv) et composition le comportant Download PDF

Info

Publication number
WO1992018630A1
WO1992018630A1 PCT/FR1992/000351 FR9200351W WO9218630A1 WO 1992018630 A1 WO1992018630 A1 WO 1992018630A1 FR 9200351 W FR9200351 W FR 9200351W WO 9218630 A1 WO9218630 A1 WO 9218630A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
infection
hcmv
sequence
compound according
Prior art date
Application number
PCT/FR1992/000351
Other languages
English (en)
French (fr)
Inventor
Jean-Michel Alonso
François Xavier DERAMOUDT
Sylvie Monnet
Catherine David
Original Assignee
Fondation Nationale De Transfusion Sanguine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondation Nationale De Transfusion Sanguine filed Critical Fondation Nationale De Transfusion Sanguine
Publication of WO1992018630A1 publication Critical patent/WO1992018630A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • COMPOUND COMPRISING A PEPTIDE SEQUENCE NEUTRALIZING HUMAN CYTOMEGALOVIRUS (HCMV) INFECTION AND COMPOSITION COMPRISING SAME
  • the present invention relates to the use of a peptide sequence of human 02 microglobulin ( ⁇ 2m) or an ohgopeptide included in this sequence, or a molecule including all or appearing of this sequence, capable of neutralizing infection by HCMV.
  • HCMV is a Herpes virus implicated in various syndromes ranging from the classic "disease of cytomegalic inclusions" of the newborn, to infectious and immunopathological complications of blood transfusions and tissue transplants, or of various latrogenic or acquired immunodeficiency syndromes, including AIDS (Merigan. TC. And Resta, S 1990, Rev. infect. Dis, 12: s 693).
  • Murine models, using MCMV. have helped to confirm the hypotheses resulting from the observation of human pathology: the decompensation of latent infection would be secondary to the immune deficiency of nitrogen, predominantly altering cell-mediated immunity (T lymphocytes and monocytes - macrophages), but secondary triggering of tissue damage (in particular interstitial pneumonia) would result from an immunopathological reaction (probably the action of cytotoxic lymphocytes against infected cells expressing viral "neoantigens”) (Shanley et al. 1982, J. Infect. Dis. 146: 388).
  • MHCI major histocompatibility class I complex
  • the inventors evaluated different synthetic peptides, the sequence of which reproduces portions of the ⁇ 2m. for their ability, when combined with HCMV, to inhibit infection of human cells and murine transfectants expressing human ⁇ 2m. The inhibitory power of HCMV infection of cells has been demonstrated for one of these peptides.
  • the present invention relates to a compound endowed in particular with an inhibitory activity of the infection of human cells by the cytomegalovirus, characterized in that it contains at least the sequence Ser-Phe-Tyr-Leu-Leu-Tyr-Tyr- Thr-Glu-Phe-Thr-Pro-Thr-Glu-Lys-Asp-Glu-Tyr-Ala-Cys-Arg-Val (522V) or a fragment of said sequence having inhibitory activities.
  • the compound according to the present invention may contain other peptide sequences and / or sequences of a non-peptide nature as will be described below. It should be understood that the amino acid sequence thus described may include other functionalities, in particular glycosylations, which are covered by the preceding definition.
  • the compound according to the present invention can be obtained by various techniques, in particular by chemical synthesis or obtained in the form of a recombinant molecule expressed by a prokaryotic or eukaryotic host.
  • a peptide containing the neutralizing sequence can also be obtained by chemical or enzymatic cleavages of the native ⁇ 2m, using agents such as: mild acid hydrolysis, hydroxylamine, CNBr, BNPS or NCS / urea, NB5 , NZB, Armillaria mellea protease, chymotrypsin, clostripain, endopeptidase Lys C, pancreatic elastase, post-proline cleavage enzyme. trypsin. staphylococcus protease V8 for example.
  • Ganciclovir and Foscarnet are the most active. Acyclovir has not been shown to work. Ganciclovir has the disadvantage of causing toxic effects for granulocytes and Foscarnet is nephrotoxic. Protocols combining polyclonal anti-HC MV immunoglobins with Ganciclovir and making it possible to reduce the dosage of the antiviral would have made it possible to limit the mortality rate from HCMV infection.
  • Anti-HCMV immunogiobulins have a beneficial effect in delaying and limiting the onset of infection after renal transplant.
  • Attenuated vaccines injected into kidney transplant recipients, would have a beneficial effect in reducing the severity of the infection.
  • One of the therapeutic approaches which is proposed in the present invention is the use of the mechanism for neutralizing viral infection by inhibiting the attachment of HCMV to its presumed receptor, ⁇ 2m, by saturating the virus with a " "peptide lure corresponding to one of the domains of the native ⁇ 2m.
  • the compound according to the invention can be used in the form of the peptide sequence or in a more elaborate form.
  • protective elements and / or carrier molecules may be elements ends resistant to peptidases: hydroxy, non-natural acid and / or amino acid for example, or protective elements of the PEG, immunoglobulin and / or albumin type or fragments derived from these products.
  • This compound can also be combined in the form of particles, nanoparticles, liposomes or the like, in particular inert and biodegradable.
  • the present invention also relates to anti-idiotypes of antibodies directed against the sequence described above.
  • an antibody directed against this peptide can mimic its structure and conformation its binding site to HCMV.
  • An anti-idiotype against this antibody may have the same inhibitory functions for HCMV infection as the neutralizing peptide and therefore be used as a substitute for the latter.
  • this peptide can be used as a vectoring agent for molecules active against HCMV (antiviral agents, interferon for example).
  • the subject of the invention is pilot drugs, that is to say comprising all or part of molecules with anti-viral activity coupled with the compounds and / or peptides according to the invention.
  • the antiviral agents that can be used are more particularly analogs of antiviral nucleosides such as Acyclovir or Ganciclovir or Foscarnet.
  • the coupling methods are known and depend on the products in question. It is now possible to carry out couplings on the NH 2 and / or COOH fractions of the peptides according to the invention.
  • the present invention also relates to the pharmaceutical composition
  • the pharmaceutical composition comprising at least one compound according to the invention, either as an active principle or as a vectorizing agent for molecules active against HCMV.
  • the compounds according to the present invention may be in any dosage form suitable for the mode of administration.
  • the dosages used obviously depend on the type of infection and its stage and must be adapted to the patient's condition.
  • Figure 1 inhibitory effect of S22V, on human fibroblasts MRC 5 and murine J27, expressing human ⁇ 2 microglobulin.
  • Figure 2 dose-dependence of the neutralizing effect of 522V on human MRC5 fibroblasts exposed to HCMV.
  • Figure 3 Effect of pre-incubation of synthetic peptides, derived from ⁇ 2m, with MRC5 cells, on their sensitivity to HCMV infection.
  • Figure 4 Absence of competition between the native zm and the peptide S22V for the neutralizing power of the latter on the HCMV.
  • Figure 5 Neutralizing effect of peptide S22V compared to that of therapeutic anti-CMV IgG.
  • the HCMV AD 169 strain was provided to us by S. Michelson (Institut Pasteur, Paris).
  • the viral inocuium is obtained from supernatants of MRC5 cells (ATCC CCL 171) cultivated in MEM medium (Gibco) supplemented with fetal calf serum (SVF) at a concentration of 10% final, and infected for a period which causes 90% cytopathic effect.
  • the HCMC stock is kept at -80 ° C.
  • the cells are first cultivated in a 24-well plate (Falcon) in MEM, 10% FCS, until the formation of a monolayer cell mat. Twenty four hours before infection the culture medium is replaced by MEM without additive.
  • the viral inoculum is mixed v / v with each product and incubated for 1 h at 37 ° C. before being brought into the presence of the target cells.
  • the proven products are:
  • a control synthetic peptide (NEOSYSTEM) (D 20K) having no sequence homology with (32m and whose amino acid sequence is:
  • a human anti-HCMV monoclonal IgG2 (JM Seigneurin, CHRU de Grenoble) was also tested in our trials.
  • the culture medium is removed after 1 8 hours of incubation of the infected cells.
  • the cells are washed twice with 0.1 M NaCI in phosphate buffer (PBS).
  • the cells are then fixed in 90% acetone for 1 5 minutes at + 4 ° C.
  • HC MV infection is detected by revelation of immediately early antigens (IEA) with a murine monoclonal antibody IgG l, (Ref: E 13 Biosoft) itself revealed by murine anti IgG immunoconjugate (H + L) the peroxidase (Pasteur Diagnosis).
  • the results presented express the average of the number of infectious units detected according to the number of cell nuclei stained by the immunoperoxidase revealed by the addition of diaminobenzidine tetrahydrochloride then H2O2.
  • the human fibroblasts MRC 5 and the murine fibroblasts 327 expressing the human 2 m are sensitive to infection by HCMV AD 169, while the control murine fibroblasts transfected with the TK gene are insensitive.
  • These results confirm the receptor role for (32m for HCMV.
  • Pre-incubation with the various preparations at a concentration of 200 ug / ml shows that the S22V peptide inhibits infection of MRC5 and 327.
  • the C225 peptide does not seems to inhibit in this trial only MRC5 infection
  • the peptide D20K was omitted from the MRC5 infection trial.
  • FIG. 2 shows the results obtained with three concentrations of the products tested against HCMV on MRC5 cells. It is confirmed that the S22V peptide brought into contact with HCMV is neutralizing and that this effect is dose-dependent.
  • Example 3 Specificity of the inhibitory effect of the peptide S22V Three synthetic peptides representing domains of the ⁇ 2m were therefore tested for their HCMV inhibitory activities in vitro. It therefore appears that a synthetic peptide of 21 aa (S-22-V) representing the amino acid sequence 61-82 of human ⁇ 2m has an inhibitory power against infection by the HCMV strain of reference AD-169, reference target cells (human fibroblasts MRC5) as well as murine fibroblasts transfected with the human ⁇ 2m gene.
  • FIG. 3 indicates that the pre-incubation of the MRC5 cells with the different peptide preparations before infection with CMV does not induce a dose-dependent neutralizing effect (the binding of the peptide to the virus is necessary for the inhibition of the infection).
  • the proposed mode of action is the inhibition of the attachment of the "coated" HCMV by the peptide to its site of attachment to the target cell.
  • AD-169 HCMV virus
  • S-22-V peptide a competition trial between S-22-V and the native ⁇ 2m was carried out.
  • a neutralization experiment was carried out for a peptide concentration of 200 ⁇ g / ml (8 ⁇ 10 -2 M) in the presence of 2, 20 and 200 mg / ml of ⁇ 2m (1.8 ⁇ 10 -4 , 1.8 ⁇ 10 -3 and 1.8 ⁇ 10 -2 M).
  • Native ⁇ 2m has no inhibitory effect on the effect of the peptide in vitro.
  • FIG. 5 indicates that the S-22-V peptide at a concentration of 200 ⁇ g / ml (8 ⁇ 10 -2 M) has an inhibitory power equivalent to that of a preparation of intravenous anti-CMV immunoglobulins (BioTransfusion : lot no. 52 01 00 10) at a dilution of 1/10 equivalent to 10 IU / ml of anti-CMV.
  • IU / ml level of anti-CMV antibody determined by ELISA method, by reference to the international standard).
  • Figure 3 Experimental neutralization of infection, in vitro, by HCMV of human MRC5 fibroblasts, pre-incubated in the presence of 2, 20 and 200 ⁇ g / ml of the peptides S22V, E23M and C22S; Results corresponding to the average of the measurements made on four wells ⁇ standard deviation.
  • Figure 4 Neutralization power of S-22-V on AD-169 in the presence of native ⁇ 2m at different concentrations.
  • Figure 5 Comparative neutralizing power between the peptide S-22-V at 200 ⁇ g / ml and the specific intravenous Ig G anti-CMV diluted to 1/10, 1/100 and 1/1000.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/FR1992/000351 1991-04-18 1992-04-17 Compose comprenant une sequence peptidique neutralisant l'infection par le cytomegalovirus humain (hcmv) et composition le comportant WO1992018630A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR91/04787 1991-04-18
FR9104787A FR2675508A1 (fr) 1991-04-18 1991-04-18 Compose comprenant une sequence peptidique neutralisant l'infection par le cytomegalovirus humain (hcmv) et composition le comportant.

Publications (1)

Publication Number Publication Date
WO1992018630A1 true WO1992018630A1 (fr) 1992-10-29

Family

ID=9412004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1992/000351 WO1992018630A1 (fr) 1991-04-18 1992-04-17 Compose comprenant une sequence peptidique neutralisant l'infection par le cytomegalovirus humain (hcmv) et composition le comportant

Country Status (2)

Country Link
FR (1) FR2675508A1 (enrdf_load_stackoverflow)
WO (1) WO1992018630A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735984A1 (fr) * 1995-06-30 1997-01-03 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005855A1 (en) * 1987-12-15 1989-06-29 Cogent Limited Human cytomegalovirus protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005855A1 (en) * 1987-12-15 1989-06-29 Cogent Limited Human cytomegalovirus protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. vol. 168, no. 3, 16 Mai 1990, DULUTH, MINNESOTA US pages 1223 - 1229; H.ODANI ET AL: 'PURIFICATION AND COMPLETE AMINO ACID SEQUENCE OF NOVEL BETA2-MICROGLOBULIN' *
NATURE. vol. 347, 25 Octobre 1990, LONDON GB pages 770 - 772; H.BROWNE ET AL: 'A COMPLEX BETWEEN THE MHC CLASS I HOMOLOGUE ENCODED BY HUMAN CYTOMEGALO-' *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735984A1 (fr) * 1995-06-30 1997-01-03 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
WO1997002344A3 (fr) * 1995-06-30 1997-03-06 Inst Nat Sante Rech Med Vaccin contre des agents infectieux, composition pour le traitement et la prevention des infections a hiv
US6113902A (en) * 1995-06-30 2000-09-05 Institut National De La Santa Et De La Recherche Medicale (Inserm) Immunogenic compositions comprising peptides from β-2-microglobulin

Also Published As

Publication number Publication date
FR2675508A1 (fr) 1992-10-23
FR2675508B1 (enrdf_load_stackoverflow) 1995-03-03

Similar Documents

Publication Publication Date Title
EP1001815B1 (fr) Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
EP1042363B1 (fr) Nouveaux immunogenes anti-hiv (toxoides), procedes de preparation et application a la prevention et au traitement du sida
CA2168268C (en) Aids and sle prophylactics
CA2215483C (fr) Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant
EP1096953B1 (fr) Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, procede de preparation et applications pharmaceutiques ou vaccinales
WO1997044462A1 (fr) Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
CA2598929A1 (fr) Epitopes de vih et composition pharmaceutique les contenant
FR2570278A1 (fr) Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
WO1992018630A1 (fr) Compose comprenant une sequence peptidique neutralisant l'infection par le cytomegalovirus humain (hcmv) et composition le comportant
EP0346430A1 (fr) Proteines et leur procede de preparation, sequences d'adn, anticorps et leur application, poxvirus, cellules transformees ou infectees et compositions pharmaceutiques utiles dans la prevention de la toxoplasmose
KR970005329B1 (ko) 포유 동물의 레트로바이러스 감염 치료용 조성물
EP0656010B8 (fr) Utilisation de peptide reconnu par une réponse immunitaire pour l'obtention de médicaments déstinés à l'induction de la supression immunitaire.
RU2130317C1 (ru) Линейные или циклические пептиды, их применение, способ лечения
WO1996004006A1 (fr) UTILISATION DE LA β2-GLYCOPROTEINE I SOUS AU MOINS UNE DE SES FORMES COMME AGENT ANTI-INFECTIEUX ET COMPOSITION PHARMACEUTIQUE CORRESPONDANTE
AU719203B2 (en) Use of proteins as anti-retroviral agents
EP0375767B1 (fr) Peptides ayant des proprietes protectrices d'un virus pathogene du type hiv dans des cellules sensibles
FR2731355A1 (fr) Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant
Marker et al. T‐Cell Effector Function and Unresponsiveness in the Murine Lymphocytic Choriomeningitis Virus Infection: I. On the Mechanism of a Selective Suppression of the Virus‐Specific Delayed‐Type Hypersensitivity Response
FR2646353A1 (fr) Utili sation de peptides contenant de la statine pour la preparation de medicaments utiles pour le traitement des maladies virales
Weinberg Effect of cyanogen bromide digested histocompatibility antigens on graft survival in mice
FR2694560A1 (fr) Nouveaux peptides viraux, anticorps dirigés contre ces peptides, procédé de préparation, application à titre de médicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
FR2739560A1 (fr) Utilisation d'un polypeptide ayant l'activite du cd16 humain soluble dans le traitement de l'infection par le virus vih
CA2084331A1 (en) Method and composition for treating viral infections
CA2309372A1 (en) Use of antibodies against the nef protein for decreasing the chemotaxis which is induced by retrovirus-infected astrocytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

122 Ep: pct application non-entry in european phase